Compare Tango Therapeutics Inc. (TNGX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Xpeng Inc - ADR — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Xpeng Inc - ADR trades at $9.45 (market cap $9.24B). The key difference: Xpeng Inc - ADR is far larger — about 2.5× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Xpeng Inc - ADR for 81 Days on average.
| TNGX | XPEV | |
|---|---|---|
Market Cap | $3.75B | $9.24B |
Volume | 9,619,106 | 6,669,510 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $28.07 |
52-Week Low | $7.50 | $9.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $2.77B | $11.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XPeng (XPEV) trades at $9.42, down 2.48% amid bearish technical signals despite strong revenue growth. The company delivered 41,256 vehicles in September 2026 and is expanding globally with new model launches. While revenue surged to $76.72 billion in 2025, net losses persist at -$1.14 billion, though margins are improving. Analyst consensus remains bullish with a $17.55 price target.
Investment outlook balances growth potential against profitability challenges. XPeng's expansion into AI robotics and European markets offers upside, but persistent losses and competitive pressures pose risks. The stock presents a speculative opportunity for investors betting on future profitability and market share gains in the evolving EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
